OMB APPROVAL
  UNITED STATES
SECURITIES AND EXCHANGE COMMISSION
Washington, D.C. 20549
OMB Number: 3235-0058
  Expires: February 28, 2022
  Estimated average burden hours per response. 2.50

 

  FORM 12b-25 SEC FILE NUMBER
   1-16467
     
    CUSIP NUMBER
  NOTIFICATION OF LATE FILING  761227305

 

(Check one):

☒ Form 10-K ☐ Form 20-F ☐ Form 11-K ☐ Form 10-Q ☐ Form 10-D ☐ Form N-CEN ☐ Form N-CSR

   
 

For Period Ended: _December 31, 2021____

☐ Transition Report on Form 10-K

☐ Transition Report on Form 20-F

☐ Transition Report on Form 11-K

☐ Transition Report on Form 10-Q

 

For the Transition Period Ended: ____________________

 

Read Instruction (on back page) Before Preparing Form. Please Print or Type.

Nothing in this form shall be construed to imply that the Commission has verified any information contained herein.

 

If the notification relates to a portion of the filing checked above, identify the Item(s) to which the notification relates:

 

PART I — REGISTRANT INFORMATION

 

RESPIRERX PHARMACEUTICALS INC.
Full Name of Registrant
 
 
Former Name if Applicable 
 
 126 Valley Road, Suite C
Address of Principal Executive Office (Street and Number)
 
 Glen Rock, New Jersey 07452
City, State and Zip Code

 

 

 

 

 

 

PART II — RULES 12b-25(b) AND (c)

 

If the subject report could not be filed without unreasonable effort or expense and the registrant seeks relief pursuant to Rule 12b-25(b), the following should be completed. (Check box if appropriate)

 

(a) The reason described in reasonable detail in Part III of this form could not be eliminated without unreasonable effort or expense;
     
(b) The subject annual report, semi-annual report, transition report on Form 10-K, Form 20-F, Form 11-K, Form N-CEN or Form N-CSR, or portion thereof, will be filed on or before the fifteenth calendar day following the prescribed due date; or the subject quarterly report or transition report on Form 10-Q or subject distribution report on Form 10-D, or portion thereof, will be filed on or before the fifth calendar day following the prescribed due date; and
     
  (c) The accountant’s statement or other exhibit required by Rule 12b-25(c) has been attached if applicable.

 

PART III — NARRATIVE

 

State below in reasonable detail why Forms 10-K, 20-F, 11-K, 10-Q, 10-D, N-CEN, N-CSR, or the transition report or portion thereof, could not be filed within the prescribed time period. (Attach extra Sheets if Needed)

 

RespireRx Pharmaceuticals Inc. (the “Registrant”) was unable, without unreasonable effort or expense, to file its Annual Report on Form 10-K for the period ended December 31, 2021 (the “Annual Report”) by the March 31, 2022 filing date applicable to smaller reporting companies due to additional time needed to complete and execute an amendment to a certain agreement, that has been negotiated and substantially agreed, but for which executed documents are not yet available. This amendment would result in changes to certain disclosures about the underlying agreement and additional subsequent event disclosures in the Annual Report. In addition, the Board of Directors (acting as the Audit Committee) of the Registrant would need to complete its review of those updated disclosures with the Registrant’s independent registered accounting firm. As a result, the Registrant is still in the process of preparing disclosure and validating information needed to complete the Annual Report and requires additional time to complete the Annual Report. The Registrant intends to file a complete Annual Report as soon as practicable within the extension period of fifteen calendar days provided under Rule 12b-25 of the Securities Exchange Act of 1934, as amended.

 

PART IV — OTHER INFORMATION

 

(1) Name and telephone number of person to contact in regard to this notification
 
  Jeff E. Margolis   (201)   444-4947
  (Name)   (Area Code)   (Telephone Number)
 
(2) Have all other periodic reports required under Section 13 or 15(d) of the Securities Exchange Act of 1934 or Section 30 of the Investment Company Act of 1940 during the preceding 12 months or for such shorter period that the registrant was required to file such report(s) been filed? If answer is no, identify report(s).
 
  Yes ☒ NO ☐
 
(3) Is it anticipated that any significant change in results of operations from the corresponding period for the last fiscal year will be reflected by the earnings statements to be included in the subject report or portion thereof?
 
  Yes ☐ NO ☒
 
  If so, attach an explanation of the anticipated change, both narratively and quantitatively, and, if appropriate, state the reasons why a reasonable estimate of the results cannot be made.

 

 

 

 

RESPIRERX PHARMACEUTICALS INC.

(Name of Registrant as Specified in Charter)

 

has caused this notification to be signed on its behalf by the undersigned hereunto duly authorized.

 

Date: March 31, 2022   By: /s/ Jeff E. Margolis
      Name: Jeff E. Margolis
      Title:

Senior Vice President, Chief Financial Officer,

Treasurer and Secretary

 

 

 

 

RespireRx Pharmaceuticals (PK) (USOTC:RSPI)
Historical Stock Chart
From Nov 2022 to Dec 2022 Click Here for more RespireRx Pharmaceuticals (PK) Charts.
RespireRx Pharmaceuticals (PK) (USOTC:RSPI)
Historical Stock Chart
From Dec 2021 to Dec 2022 Click Here for more RespireRx Pharmaceuticals (PK) Charts.